Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability and Activity of Ibudilast (MN-166) in Subjects With Progressive Multiple Sclerosis

Next Previous
Trial Profile

A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability and Activity of Ibudilast (MN-166) in Subjects With Progressive Multiple Sclerosis

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 29 Jan 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ibudilast (Primary)
  • Indications Multiple sclerosis
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Acronyms SPRINT-MS
  • Sponsors MediciNova

    • Most Recent Events

    • 01 Jan 2024 Results determining whether baseline MIF levels predict imaging outcomes and assessing the effects of ibudilast on serum and cerebrospinal fluid (CSF) MIF levels in people with PMS treated with ibudilast, published in the Multiple Sclerosis Journal
    • 01 Dec 2023 Results investigating the treatment effect of ibudilast on thalamic atrophy more than 96 weeks, published in the Multiple Sclerosis Journal
    • 01 Sep 2023 Results evaluating the effect of ibudilast on thalamic tissue integrity and volume, published in the Multiple Sclerosis Journal
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top